Exact Sciences (EXAS) Reports Q4 Loss of $0.38

Exact Sciences (NASDAQ: EXAS) reported Q4 EPS of ($0.38), versus ($0.17) reported last year. Revenue for the quarter came in at $1.15 million, versus $1 million reported last year.

Exact ended 2014 with cash, cash equivalents and marketable securities of $282.8 million, compared to $133.3 million at Dec. 31, 2013.

“We are very pleased with our 2014 accomplishments and the success we’re having with Cologuard in the short time since CMS’s final coverage decision,” said Kevin T. Conroy, the company’s chairman and CEO. “More than 4,000 physicians ordered at least one test by year end and we reported over 4,000 Cologuard test results.

“We also are excited by the success we’ve had with engaging patients through our customer support center,” Mr. Conroy said. “Our active engagement of patients who had been prescribed the test but hadn’t returned their collection kit caused our patient compliance rate to double. Our priorities in 2015 are to continue to grow our Cologuard business and provide world-class physician and patient engagement, while advancing our product pipeline.”

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.

You May Also Be Interested In

• JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
• Litchfield Hills Starts NextPlat (NXPL) at Buy
• NXP Semiconductors names Mike Lucarelli as new investor relations head